Cutaneous Lupus Erythematosus Clinical Trials | A Drug Pipeline Analysis Report 2023 | DelveInsight
United States, Nevada, Las Vegas, DelveInsight’s ‘Cutaneous Lupus Erythematosus Pipeline Insight 2023‘ report provides comprehensive global coverage of available, marketed, and pipeline Cutaneous Lupus Erythematosus therapies in various stages of clinical development, major pharmaceutical companies are working to advance the pipeline space and future growth potential of the Cutaneous Lupus Erythematosus pipeline domain.
Key Takeaways from the Cutaneous Lupus Erythematosus Pipeline Report
- Over 12+ Cutaneous Lupus Erythematosus pipeline therapies are in various stages of development, and their anticipated acceptance in the Cutaneous Lupus Erythematosus market would significantly increase market revenue.
- Leading Cutaneous Lupus Erythematosus companies developing novel drug candidates to improve the Cutaneous Lupus Erythematosus treatment landscape include Biogen, Sanofi, and others.
- Promising Cutaneous Lupus Erythematosus pipeline therapies in various stages of development include BIIB059, SAR443122, and others.
Cutaneous Lupus Erythematosus Overview
Lupus erythematosus (LE) is a connective tissue disease and autoimmune disorder that can affect one or several organs. Circulating autoantibodies and immune complexes are pathogenic due to loss of normal immune tolerance. The clinical features of LE are highly variable. LE nearly always affects the skin to some degree. Cutaneous LE comprises several chronic and relapsing LE-specific and LE-nonspecific inflammatory conditions.
Cutaneous Lupus Erythematosus Pipeline Analysis: Drug Profile
BIIB059: Biogen
Litifilimab (known as BIIB059), discovered and developed in-house by Biogen scientists, is a humanized IgG1 monoclonal antibody (mAb) targeting blood dendritic cell antigen 2 (BDCA2) and is being investigated for the potential treatment of systemic lupus erythematosus (SLE) and cutaneous lupus erythematosus (CLE). Currently it is being evaluated in Phase II clinical trial in Participants with Active Subacute Cutaneous Lupus Erythematosus (SCLE) and/or Chronic Cutaneous Lupus Erythematosus (CCLE) with or without Systemic Manifestations and Refractory and/or Intolerant to Antimalarial Therapy.
Discover more about the emerging Cutaneous Lupus Erythematosus drugs @ Cutaneous Lupus Erythematosus Treatment Drugs
Cutaneous Lupus Erythematosus Key Companies
- Biogen
- Sanofi
Cutaneous Lupus Erythematosus Pipeline Therapies
- BIIB059
- SAR443122
Cutaneous Lupus Erythematosus Pipeline Therapeutics Assessment
- By development stage
- By product type
- By route of administration
- By molecule type
- By MOA type
Scope of the Cutaneous Lupus Erythematosus Pipeline Report
- Coverage: Global
- Key Cutaneous Lupus Erythematosus Companies: Biogen, Sanofi, and others
- Key Cutaneous Lupus Erythematosus Pipeline Therapies: BIIB059, SAR443122, and others
Find out more about the Cutaneous Lupus Erythematosus treatment options in development @ Cutaneous Lupus Erythematosus Clinical Trials
Table of Contents
1. Introduction
2. Executive Summary
3. Overview
4. Pipeline Therapeutics
5. Late-Stage Products (Phase III)
6. Mid-Stage Products (Phase II)
7. Early Stage Products (Phase I/II)
8. Preclinical Stage Products
9. Discovery Stage Products
10. Therapeutic Assessment
11. Inactive Products
12. Collaborations Assessment- Licensing / Partnering / Funding
13. Unmet Needs
14. Market Drivers and Barriers
15. Appendix
16. About DelveInsight
Request for a sample report to know more about key companies leading in the Cutaneous Lupus Erythematosus Pipeline Segment
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Kritika Rehani
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/
